Lab-on-a-Chip (LOC) is a technology that shrinks laboratory functions such as sample handling, mixing, separation, and detection onto a single microfluidic chip, often just a few square centimeters in size. In medical devices, LOC systems power point-of-care diagnostics, letting a lab-grade test run outside a central laboratory using microliter sample volumes.
What is Lab-on-a-Chip (LOC)?
A Lab-on-a-Chip (LOC) device integrates multiple laboratory processes onto a single microfabricated substrate made from glass, silicon, or a polymer such as cyclic olefin copolymer. Channels smaller than a human hair route nanoliter to microliter volumes of sample and reagent through mixing chambers, reaction zones, and a detection element, often optical, electrochemical, or fluorescence-based. The chip typically sits inside a companion reader that supplies pumping, temperature control, and signal processing.
LOC development sits at the intersection of microfabrication, fluidics engineering, assay chemistry, and embedded software, and moves from proof of concept through architecture, verification, and design transfer before becoming a regulated in vitro diagnostic (IVD) product.
Why Lab-on-a-Chip (LOC) matters in medical device development
The appeal of Lab-on-a-Chip (LOC) technology is speed and access. A test that once needed a central lab and a trained technician can now run in a clinic, pharmacy, or field setting within minutes. That shift carries regulatory weight: a companion diagnostic built on an LOC platform can influence which drug a patient receives, so an assay drifting out of specification has direct patient-safety consequences.
Cost and timeline exposure follow the same pattern. A design change, a new substrate lot, or a firmware update can shift assay performance in ways hard to catch, since chip, reader, and reagents form one system. Manufacturers treating chip and reader as separate efforts often discover integration problems late, when a fix costs far more.
How Lab-on-a-Chip (LOC) systems work
An LOC system is built from a small number of core elements that work together to move the sample through an assay:
- Sample introduction: a port or cartridge interface accepting blood, saliva, urine, or another fluid, often with a built-in separation step such as a plasma filter.
- Microfluidic network: etched or molded channels, valves, and chambers that route and meter fluid using capillary action, centrifugal force, or applied pressure.
- Reaction zone: where the assay chemistry, an immunoassay, nucleic acid amplification, or enzymatic reaction, takes place.
- Detection element: an optical, electrochemical, or fluorescence sensor converting a biochemical signal into data.
- Reader or analyzer: supplies power, temperature control, fluidic actuation, and signal processing, and reports the result.
Interoperability between chip and reader is its own engineering concern: ISO 22916 sets requirements for dimensions, connections, and initial device classification so chips and interconnects from different sources can be combined without a custom fit each time.
Most LOC-based products are in vitro diagnostic medical devices. In the US, they fall under FDA’s IVD provisions, including 21 CFR Part 809 labeling rules, with quality systems governed by the Quality Management System Regulation (21 CFR Part 820), which incorporates ISO 13485 by reference. CLIA complexity categorization determines the oversight a point-of-care LOC test needs in a clinical setting. In the EU, LOC-based IVDs fall under Regulation (EU) 2017/746, covering risk classification, performance evaluation, and post-market surveillance. Reader software follows an IEC 62304 lifecycle, and risk management follows ISO 14971 across chip, reagents, and reader as one system.
Common challenges and best practices
Teams shipping their first LOC product tend to underestimate how tightly the chip, reagents, and reader are coupled. A change to channel geometry can shift reaction kinetics enough to move an assay outside its validated range, even when no single component fails its own test.
Recurring issues include cross-lot variability in molded or etched chips, since small dimensional shifts change fluid flow and mixing time, and reagent instability under real shipping conditions, which is easy to miss when early testing uses only freshly prepared reagent. Reader firmware often gets treated as a late add-on rather than part of verification from day one, pushing bugs into design transfer or, worse, into the field.
Good programs verify chip, reagent, and reader together as one system, set process controls for chip fabrication early, and run stability studies against real shipping conditions instead of lab-ideal ones. Clear traceability from user need through chip specification to verification test also eases design changes later with a notified body or FDA reviewer.
How SJML helps with Lab-on-a-Chip (LOC)
SJML works across the LOC stack, from chip and cartridge design through reader engineering, manufacturing, and regulatory submission. Design and engineering teams handle microfluidic architecture, embedded software, and reader electronics under a design-controls process with risk management and usability engineering built in, backed by in-house labs for electrical safety and reliability testing.
SJML also operates cleanroom environments suited to cartridge assembly and PCBA for the reader, alongside process validation and supplier qualification for specialty materials. Its QARA Compliance-as-a-Service team supports regulatory strategy, FDA and EU IVDR submissions, technical file preparation, and post-market surveillance planning, and has direct experience with point-of-care and microfluidics IVD platform programs.
Talk to SJML’s engineering team →
Frequently asked questions
Lab-on-a-Chip (LOC) describes chip-level technology that miniaturizes lab processes onto a single microfluidic device. Point-of-care (POC) testing describes where a test happens: at a bedside, clinic, or pharmacy rather than a central lab. Many POC tests use LOC technology, but POC also covers non-chip formats such as lateral flow strips, so the two terms describe different layers of the same product.
Most Lab-on-a-Chip (LOC) products used for diagnosis or monitoring are regulated as in vitro diagnostic (IVD) medical devices under FDA’s IVD framework and CLIA rules in the US and Regulation (EU) 2017/746 in the EU. Risk classification depends on intended use: a companion diagnostic or a test for a life-threatening infection is classified higher than a general wellness screen.
Common standards include ISO 13485 for the quality management system, ISO 14971 for risk management across chip, reagent, and reader, IEC 62304 for reader and analysis software, and IEC 60601-1 for electrical safety of the reader instrument. ISO 22916 addresses the interoperability of microfluidic device dimensions and connections, which matters when chips and connectors come from different suppliers.
An LOC platform couples chip fabrication, reagent chemistry, and reader hardware and software into one system, so a change in any single element can shift assay performance. Verification has to test the combination under real shipping, storage, and use conditions rather than each part alone. That system-level testing, plus clinical performance studies, adds time compared with a standalone instrument reading a pre-validated reagent.
Yes. Many LOC platforms pair one shared reader with interchangeable cartridges, each carrying different assay chemistry for a specific analyte or panel. This spreads reader development and clearance cost across several tests, though every new cartridge assay still needs its own analytical and clinical validation before reaching the market.
Related terms
- Microfluidics
- Point-of-Care (POC) Diagnostics
- In Vitro Diagnostic (IVD) Device
- IEC 62304 Software Lifecycle
- ISO 22916
